The confectionery landscape is undergoing a transformation, driven by evolving consumer demands for healthier indulgences. One of the most notable trends is the rise of high-protein candy. Once seen as an indulgent treat, candy is now being reimagined to include nutritional benefits.

Protein has become a star ingredient in the global snack market, valued for its role in muscle growth, energy, stamina, and weight management. In fact, 42% of global consumers identify protein as the most important ingredient when choosing snacks (1).

With promising market forecasts, supporting scientific research, and cutting-edge innovations like SOLUFORM^®️ PE gelatin by GELITA, high-protein candy is emerging as a game-changing segment in confectionery.

We all know that feeling... a sudden, pounding headache hits you, making it impossible to focus. Or perhaps it's throbbing toothache or debilitating period pain. No matter the source of your discomfort, when pain strikes, quick relief is essential. Our RAPISOL^® fast-release gelatin delivers just that in a softgel capsule designed for rapid dissolution of its pain-relieving contents.

Speedy softgels

While traditional tablets are capable of incorporating a high concentration of active ingredients in a solid form, they require more time to break down in the digestive system. This delay can mean inconsistent absorption rates, with painkillers such as aspirin, ibuprofen and acetaminophen/paracetamol possibly not reaching the bloodstream as quickly as necessary for effective pain relief. In contrast, softgels, with their liquid fillings, dissolve faster, allowing the body to rapidly absorb the active ingredients.

The fortified gummy market is booming, driven by a growing consumer demand for convenient and delicious ways to consume vitamins, minerals, and other health-promoting ingredients. However, this rapid growth has exposed significant challenges in the traditional production methods. Manufacturers have often had to compromise on efficiency, taste, or safety.

GELITA's new product, CONFIXX^®, is putting an end to these compromises, revolutionizing the industry by offering an innovative solution to longstanding challenges.

At the heart of every company lies the determination to innovate, evolve and better serve its customers. Sometimes this means changing product names to better reflect their positioning and market potential. That’s why we have decided to rebrand our controlled release portfolio. This change highlights our ongoing commitment to improvement and allows us to more clearly communicate the unique properties of each product.

Why are we rebranding?

Picture each of our products as a unique character in a play, with their own strengths and traits. Our rebranding is designed to give each of these characters their moment in the spotlight. By revealing what makes each product special, we can better address your individual needs and specific challenges, and lay the foundation for our exciting innovations still to come. So be sure to stay tuned! We are thrilled to introduce you to our newly revamped portfolio, where each product has been thoughtfully crafted to meet specific needs and excel in its field.

Imagine a place where leading experts for pharma and life science applications, product formulation, marketing and regulatory affairs could come together to brainstorm exciting new ideas and solutions. We had that vision, too, which is why we created GELITA Pharma Institute (GPI) to allow our passion to meet your potential. Let us take you on a journey through what makes GPI a unique and invaluable partner in the pharmaceutical industry, and how we can help your business thrive.

Vaccinations are among the most successful tools at the medical profession’s disposal, helping to prevent numerous infectious diseases such as measles, hepatitis and, more recently, Covid-19. The effectiveness of vaccinations relies heavily on their stability. Depending on the type of vaccine, the inclusion of stabilizing agents can be crucial for the protection of the active pharmaceutical ingredient. Many stabilizers in live, attenuated vaccines are enriched with protein excipients such as gelatin and human albumin. Gelatin is classified as GRAS (Generally Recognized As Safe) and is generally known to have an extremely rare incidence of anaphylaxis (one per 2 million cases) and is therefore considered to be a safe stabilizer [1]. As a key component for the lyophilization process, it helps safeguard vaccines from temperature-related effects. That’s why we at GELITA have developed a unique solution: VACCIPRO^®, a gelatin hydrolysate that is used by our customers to protect and thus enhance the stability of vaccines.